Connect With a Concentrated Community of MIDD Experts
Build High-Value Relationships With Director-Level Decision-Makers
As MIDD groups grow within big pharma and biotech, the practitioners setting modelling strategy and the people evaluating external partners are increasingly the same senior audience. This summit brings together pharmacometricians, clinical pharmacologists and QSP scientists at Director level and above, in a setting built for direct conversation rather than passing exhibition traffic, through dedicated networking, roundtables and 1-to-1 meetings.
Position Your Solutions Against Current Implementation Questions
Biopharma teams attending are focused less on whether to use MIDD and more on how to implement it differently: where AI can be integrated into existing modelling workflows without undermining regulatory confidence, how to apply the finalized ICH M15 standard to submission types it doesn't yet directly address, and how to embed MIDD earlier in the development process rather than adding it in after key decisions are made. This summit puts your organization in front of that conversation, with the opportunity to show how your modelling, simulation, or consultancy capability supports these specific approaches.
Raise Your Visibility in a Specialized, Hard-to-Reach Community
MIDD, pharmacometrics and quantitative pharmacology audiences are narrow and senior, which makes them difficult to reach through broad marketing alone. Partnering with the summit puts your organization in front of this audience through speaking opportunities, curated networking and brand exposure across an event built specifically for this community, rather than folded into a broader clinical pharmacology or drug development meeting.
What to Expect?
Engage a Senior Audience of Biopharma Experts
Every attendee is Director level or above, working directly in pharmacometrics, clinical pharmacology, QSP or a closely adjacent function; meaning every conversation is with someone who can make or influence a buying decision.
Present to a Small, Focused Group
With attendee numbers capped, sponsors aren't one of a hundred booths competing for attention. Speaking slots, roundtables and networking sessions are structured, so your organization gets direct engagement.
Hear Where Current Approaches Fall Short
Sessions cover the specific technical and regulatory issues teams are working through now, including AI validation and data limitation in early-phase modelling, giving a clearer picture of where demand for new tools or consultancy support is likely to grow.
Meet Teams Evaluating External Support
Some attendees are deciding whether to build MIDD capability internally or bring in external modelling, simulation or consultancy support, and are doing so during the event itself.
Build Relationships That Outlast the Event
Because the group is small enough that attendees know each other by the end of day three, relationships formed here tend to continue past the summit itself, in a way that's harder to achieve at larger, higher-volume meetings.
Key Services & Solutions
Our attendees are looking for service and solution providers with capabilities in the below areas but not limited to:
PBPK & Physiologically Based Modelling
Platforms and services supporting PBPK modelling for first-in-human dose prediction, drug-drug interaction assessment and population-specific dosing.
QSP Platforms & Systems Pharmacology Consultancy
Quantitative systems pharmacology solutions that bridge biology and pharmacology to predict clinical outcomes and optimize therapeutic strategy.
Clinical Trial Simulation & Design Support
Simulation platforms and services that inform trial design, patient selection, and adaptive protocol decisions ahead of costly late-phase studies.
MIDD-Focused CROs & Modelling Consultancies
Full-service and specialist consultancies offering modelling and simulation as a core service, from preclinical translational work through to regulatory-ready submission packages.
Data & Analytics Infrastructure for MIDD
Platforms supporting data integration, model governance, and cross-program reuse of modelling and simulation outputs.
Broader CROs Offering Modelling as Part of a Wider Service
Preclinical and clinical CROs where in silico modelling sits alongside a broader service offering, rather than being the sole focus.
Regulatory & Submission Strategy Support for MIDD
Consultancy and advisory support helping teams structure model-informed evidence for submission under ICH M15 and equivalent regional frameworks.
Attending Companies Included
Audience Composition
Company Type
Attendee Seniority
Get in Touch
Take advantage of our bespoke sponsorship opportunities to achieve your commercial goals. Email us if you would like to get involved and discuss a bespoke package suited to your needs.
